In this article, we will discuss Pomalidomide (Dosage Overview). So, let’s get started.
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating Pomalidomide.
The recommended starting dose of Pomalidomide is 4 mg once daily orally on Days 1-21 of repeated 28-day cycles until disease progression.
Pomalidomide may be given in combination with dexamethasone.
Pomalidomide may be taken with water. Inform patients not to break, chew or open the capsules. Pomalidomide should be taken without food (at least 2 hours before or 2 hours after a meal).